Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cryoport, Inc. (NASDAQ: CYRX) on March 3, 2021, covering events that occurred on February 25, 2021. The filing addresses corporate governance changes, specifically the election of a new director and an amendment to the company's equity incentive plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate actions rather than financial performance results.
Material Changes
- Election of Director: The Board elected Linda Baddour as a director, effective March 15, 2021. She will receive standard non-employee director compensation as outlined in the 2020 proxy statement.
- Equity Plan Amendment: The Board approved the first amendment to the 2018 Omnibus Equity Incentive Plan. Changes include clarifying provisions for international participants, changing the governing law from California to Nevada, and making administrative clarifications.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, risk factors, or management commentary regarding future financial performance. The primary focus is on the qualifications of the new director, Ms. Baddour, who brings over 20 years of experience in healthcare and life sciences, including a prior role as CFO of PRA Health Sciences, Inc.
Key Facts for Investor Verification
- Verify the effective date of Linda Baddour's board membership (March 15, 2021).
- Review the full text of the amended 2018 Omnibus Equity Incentive Plan (Exhibit 10.1) for specific administrative changes.
- Confirm Ms. Baddour's compensation structure aligns with the 2020 definitive proxy statement.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.